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Small nucleolar RNAs (snoRNAs) are non-coding RNAs that form ribonucleoproteins to guide covalent modifications of
ribosomal and small nuclear RNAs in the nucleus. Recent studies have also uncovered additional non-canonical roles for
snoRNAs. However, the physiological contributions of these small RNAs are largely unknown. Here, we selectively deleted
four snoRNAs encoded within the introns of the ribosomal protein L13a (Rpl13a) locus in a mouse model. Loss of Rpl13a
snoRNAs altered mitochondrial metabolism and lowered reactive oxygen species tone, leading to increased glucosestimulated insulin secretion from pancreatic islets and enhanced systemic glucose tolerance. Islets from mice lacking Rpl13a
snoRNAs demonstrated blunted oxidative stress responses. Furthermore, these mice were protected against diabetogenic
stimuli that cause oxidative stress damage to islets. Our study illuminates a previously unrecognized role for snoRNAs in
metabolic regulation.

Introduction

Box C/D snoRNAs are short noncoding RNAs containing conserved
C and D box consensus motifs that form ribonucleoproteins with
NOP56, NOP58, 15.5 kDa, and the methyltransferase fibrillarin (1).
These ribonucleoproteins localize to nucleoli, where their canonical function is to serve as guides to target specific sites on ribosomal
RNAs (rRNAs) or small nuclear RNAs (snRNAs) for 2′-O-methylation through a short stretch of antisense complementarity (10–21
nucleotides). In vertebrates, this function has been demonstrated
experimentally for some box C/D snoRNAs and is predicted for
others. The observation that animals homozygous for knockout of
fibrillarin are inviable indicates that functions of box C/D snoRNAs
as a class are essential for normal development (2).
Genetic studies have suggested an expanding functional repertoire for snoRNAs beyond their well-established roles in modification and processing of rRNAs and snRNAs (3). Dysregulated
snoRNA expression has been associated with altered splicing in
the developmental syndromes, Prader-Willi and tetralogy of Fallot
(4, 5), and snoRNAs U50, ACA11, and ACA42 have been shown to
modulate tumor proliferation in vivo (6–9). Nonetheless, the physiological consequences of perturbation of expression of most mammalian snoRNAs remain unexplored, and no animal models exist
with selective and complete loss of function for any snoRNAs.
Our laboratory’s studies have demonstrated that box C/D
snoRNAs encoded by introns of the Rpl13a locus function as critical mediators of cell death in response to metabolic and oxidative stress in cultured cells (10–12). The observations that this role
can be dissociated from changes in the 2′-O-methylation status of
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predicted ribosomal RNA targets and that the Rpl13a snoRNAs
accumulate in the cytosol during oxidative stress suggest that
the Rpl13a snoRNAs may function through noncanonical mechanisms. The goal of this study was to determine the physiological
role of these noncoding RNAs.

Results

Generation of Rpl13a-snoless mice. Our previous work demonstrated a critical role for box C/D snoRNAs U32a, U33, U34, and
U35a, embedded within 4 introns of the Rpl13a locus (Figure 1A),
in the cellular response to lipotoxic and oxidative stress (10). The
observation that loss of function of the individual snoRNAs in
cultured cells is not sufficient to confer resistance to metabolic
stress suggests that these 4 snoRNAs function in concert in stress
response pathways. Therefore, to probe the long-term physiological consequences of loss of function of Rpl13a snoRNAs, we
generated a model with simultaneous loss of all 4 box C/D snoRNAs encoded in this locus. Since deletion of the RPL13a protein
in Drosophila is embryonic lethal (13), our goal was to selectively
modify 4 snoRNA-hosting introns without perturbing expression
of the exon-encoded ribosomal protein. This was accomplished
using a single recombination event to replace the locus with an
allele from which the snoRNAs were selectively deleted (Figure 1, A–C, and Supplemental Figure 1; supplemental material
available online with this article; doi:10.1172/JCI88069DS1). No
known regulatory regions overlap with these 4 snoRNAs, and
these intronic sequences are relatively depleted of H3K27 histone
marks that are often found near regulatory regions.
Homozygous Rpl13a snoRNA loss-of-function mice (referred
to hereafter in text as Rpl13a-snoless and in figures as -/-) were
live-born at normal Mendelian ratios, were fertile, and displayed
no overt pathophysiological phenotype under standard housing,
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Figure 1. Generation of mice lacking Rpl13a
snoRNAs. (A) WT locus and targeting construct (–/–) with exons in black and intronic
snoRNAs in gray rectangles. (B) Representative Southern blot from F1 (+/–) and WT
offspring (n = 5 experiments) using probe
indicated in A. (C) Primers (straight arrows)
and predicted size (nucleotides) of genotyping
PCR products, above. Representative agarose
gel of PCR products from tail DNA is shown
below (n > 10 experiments).

feeding, and breeding conditions. Body weight and body composition were indistinguishable between Rpl13a-snoless and WT mice
(Supplemental Figure 2, A and B). The Rpl13a-snoless mice were
deficient in expression of the 4 intronic snoRNAs from this locus,
but Rpl13a mRNA and protein levels were indistinguishable from
those of WT controls (Figure 2, A and B), and expression of other
snoRNAs was unchanged (Supplemental Figure 2C). Fibroblasts
from Rpl13a-snoless embryos (MEFs) had significantly lower levels of cellular superoxide and hydrogen peroxide under normal
growth conditions (Figure 2, C and D). Furthermore, following
brief exposure to exogenous hydrogen peroxide, Rpl13a-snoless
MEFs had diminished ability to amplify ROS. Lower basal ROS
tone and resistance to ROS stimulation are consistent with the
phenotype of the previously reported mutant Chinese hamster
ovary cell line, in which decreased expression of the Rpl13a sno
RNAs caused diminished oxidative stress responses (10).
Altered glucose homeostasis in Rpl13a-snoless mice. ROS participate in physiologic signaling cascades that regulate insulin
secretion. Therefore, we assessed systemic glucose metabolism in Rpl13a-snoless mice. Fasting plasma glucose and insulin
levels were indistinguishable between WT and Rpl13a-snoless
mice; however, glucose tolerance test (GTT) revealed enhanced
glucose tolerance with lower peak glucose excursion and
decreased AUC following an intraperitoneal glucose bolus (Figure 3A). To understand the cause of these changes in glucose
metabolism, we used a sensitive Singulex single molecule tracking method to quantify fasting serum insulin and insulin levels
at the 30-minute time point of the GTT, the point at which the
greatest difference in serum glucose was observed between the
genotypes. Serum insulin was significantly increased in Rpl13asnoless mice at the 30-minute time point (Figure 3B), implicating enhanced release of insulin into the circulation in response
to a glucose challenge as the cause of improved glucose tolerance. By contrast, glucose levels during insulin tolerance test
(ITT) were similar between the genotypes (Figure 3C), further

suggesting that the lower peak glucose excursion resulted not
from alterations in peripheral insulin sensitivity, but rather from
a difference in insulin secretion.
Rpl13a-snoless islets have enhanced insulin secretion. To investigate the physiological basis of increased insulin levels following a
glucose challenge, we examined pancreatic tissue of 8-week-old
WT and Rpl13a-snoless animals. β Cell mass as determined by
morphometric analysis was indistinguishable between the genotypes (Figure 4A). Protein and insulin content of isolated islets
were also not different between WT and Rpl13a-snoless mice (Figure 4, B and C). Nonetheless, consistent with enhanced insulin
secretion and glucose tolerance in vivo, Rpl13a-snoless islets had
a 51% increase in glucose-stimulated insulin secretion (GSIS; Figure 4D). Similar insulin release from islets of the two genotypes
in response to potassium chloride and glibenclamide indicated that the secretory machinery downstream of the KATP channel is intact in Rpl13a-snoless islets (Figure 4E). Consistent with
increased insulin secretion at stimulatory glucose concentrations,
Rpl13a-snoless islets demonstrated increased calcium oscillations,
and these differences were greatest at 8 mM and 16 mM glucose
(Figure 4F and Supplemental Figure 3). We confirmed that Rpl13a
snoRNAs are expressed in WT, but not Rpl13a-snoless, islets (Figure 4G). Together, these findings suggest that enhanced glucose
tolerance in Rpl13a-snoless mice results from greater islet insulin
secretion following glucose challenge.
Increased mitochondrial leak and lower ROS in Rpl13a-snoless
islets. Glucose stimulates insulin secretion through its metabolism
to produce “metabolic coupling factors” that regulate the cellular
machinery for insulin secretion (14). To assess islet glucose metabolism and mitochondrial function, we quantified oxygen consumption rates (OCR) in isolated WT and Rpl13a-snoless islets at baseline and following serial addition of modulators that target specific
components of the electron transport chain. At 3 mM glucose, basal
and maximal respiration, ATP production, and spare respiratory
capacity were comparable between the genotypes, with a large
jci.org   Volume 126   Number 12   December 2016
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Figure 2. Rpl13a-snoless mice demonstrate lower ROS tone. (A) RT-qPCR-quantified expression of Rpl13a snoRNAs and mRNA (relative to Rplp0) in WT and
Rpl13a-snoless (–/–) fibroblasts. Mean + SEM for n = 3 independent experiments. (B) Representative Western blot of RPL13a protein in embryos (n = 4 mice/
genotype). (C) MitoSOX staining of embryonic fibroblasts. Mean fluorescence of 104 cells/sample (+SEM) for n = 4 independent experiments. (D) DCF staining of
embryonic fibroblasts under basal growth conditions and following exposure to 100 μM H2O2 for 10 minutes. n = 3 independent experiments. *P < 0.005 for –/– vs.
WT determined by unpaired t test. rel, relative.

proton leak relative to ATP production in both genotypes (Figure
5A), similar to results previously described in WT islets (15). At 20
mM glucose, basal and maximal respiration were substantially
increased in Rpl13a-snoless islets relative to WT, which was due to
a large increase in proton leak, but oxygen consumption for ATP
production was not significantly different (Figure 5B). Dynamic
OCR measurements — for which WT and Rpl13a-snoless islets
were initially incubated in 3 mM glucose, followed by addition of
glucose to 20 mM in the same wells — demonstrated similar OCR
under basal conditions, with divergence in response only under
stimulatory conditions (Figure 5C). These results indicate that
Rpl13a-snoless islets have altered mitochondrial efficiency specifically during metabolic stress conditions. Nonetheless, morphology
of β cell mitochondria and quantity of mitochondrial DNA per cell
were indistinguishable between WT and Rpl13a-snoless mice (Supplemental Figure 4, A and B).
Mitochondria are a major source of ROS in all cell types during
substrate oxidation and oxidative phosphorylation, with production
of superoxide or hydrogen peroxide at 11 distinct mitochondrial
sites (16). Given that uncoupled respiration decreases mitochondrial hydrogen peroxide production during metabolic challenge (17,
18), we hypothesized that increased proton leak in Rpl13a-snoless
islets could lead to lower islet ROS. Similar to our observations in
MEFs, isolated, intact islets from Rpl13a-snoless mice demonstrated a 60% decrease in basal superoxide content compared with WT
islets, as assessed by staining with dihydroethidium (DHE) (Figure
6A). Dissociated islets demonstrated significantly lower intracellular hydrogen peroxide (DCF) and superoxide (DHE) not only under
basal conditions, but also following exposure to exogenous hydrogen peroxide (Figure 6B) or menadione, a rapid inducer of superoxide (Figure 6C). Consistent with the known ability of high glucose
to induce islet ROS (19), dispersed WT islets had higher hydrogen
peroxide content under stimulatory (20 mM) compared with basal
(3 mM) glucose conditions (Figure 6D). Dispersed Rpl13a-snoless
islets demonstrated significantly lower ROS under both conditions. General antioxidant capacity measured in lysates of WT and
Rpl13a-snoless islets was indistinguishable as determined using the
Trolox equivalent antioxidant capacity assay (Supplemental Figure
4C), suggesting that differences in ROS related to differences in
4618
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ROS production. Given that ROS can function to inhibit GSIS (20,
21), our findings suggest a model in which enhanced mitochondrial proton leak and the resulting lower ROS in Rpl13a-snoless islets
leads to greater insulin secretion.
To gain further mechanistic insight into these observations,
we carried out RNAseq analysis of Rpl13a-snoless and WT islets.
We observed 2-fold or greater differences in the expression of
only 6 genes, none of which encodes a mitochondrial protein or is
known to have direct effects on the response to ROS (Supplemental Tables 1 and 2). None is predicted bioinformatically to have
strong binding sites for U32a, U33, U24, or U35a (22). Our findings suggest these 6 genes are unlikely to be direct targets of the
Rpl13a snoRNAs, and effects of Rpl13a snoRNAs on gene expression may be post-transcriptional.
Rpl13a-snoless mice are resistant to diabetogenic stimuli. ROS
have also been implicated in the pathogenesis of diabetes in animal
models and in humans (23–27). The enhanced ROS tolerance of
Rpl13a-snoless islets suggested that Rpl13a-snoless mice would have
improved responses to diabetogenic stimuli. We therefore examined the susceptibility of Rpl13a-snoless mice to treatment with low
dose streptozotocin, an antibiotic known to cause β-cell oxidative
stress and cell death (28). After administration of streptozotocin
or sodium citrate as control, mice were followed for an additional
8 weeks. Hyperglycemia was less severe in streptozotocin-treated
Rpl13a-snoless mice compared with WT mice (Figure 7A). GTT
performed 8 weeks after streptozotocin treatment revealed lower
blood glucose in Rpl13a-snoless mice at each time point (Figure 7B).
In sodium citrate–treated mice, fasting blood glucose was indistinguishable between the genotypes, with persistence of improved
glucose tolerance in Rpl13a-snoless mice at 16 weeks of age (Supplemental Figure 5). To gain insight into the mechanism of this protection, we harvested pancreas tissue from an independent cohort
of animals 5 days after streptozotocin treatment. While markers of
inflammation and β cell replication were indistinguishable between
the genotypes (Supplemental Figure 5), streptozotocin-induced
accumulation of the oxidatively modified lipids 4-hydroxynonenal
and 3β,5α,6β-cholestanetriol (triol) was prevented in Rpl13a-snoless
mice (Figure 7, C and D). Furthermore, TUNEL staining of insulinpositive β cells was decreased by 50% in Rpl13a-snoless animals
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Figure 3. Rpl13a-snoless mice have improved glucose tolerance and insulin
secretion. (A) Mean (+SEM) blood glucose and AUC during GTT in 8-week-old
female WT and –/– mice. n = minimum of 9 mice/genotype. (B) Mean serum
insulin (+SEM) at 0 and 30 minutes of GTT. n = minimum of 8 mice/genotype.
(C) Mean blood glucose (+SEM) during ITT. n = minimum of 7 mice/genotype.
**P < 0.0005; *P < 0.05 for –/– vs. WT determined by unpaired t test.

compared with WT controls (Figure 7E). This indicates that Rpl13a
snoRNAs function in propagation of oxidative stress in the pancreas
and in β cell apoptosis in response to streptozotocin.
We further evaluated the effect of loss of Rpl13a snoRNAs in
other murine models of diabetes. In the Akita model of diabetogenesis, the Ins2C96Y allele causes endoplasmic reticulum and oxidative
stress, leading to β cell apoptosis and diabetes (29, 30). Loss of function of the Rpl13a snoRNAs decreased the degree of hyperglycemia
in both male and female mice carrying the Ins2C96Y allele (Figure
7F). In the non-obese diabetic (NOD) model, oxidative damage in
pancreatic β cells, β cell destruction, and the development of diabetes are mitigated by treatment with inhibitors of ROS-producing
enzymes, treatment with chemical ROS scavengers, or β cell–
specific overexpression of antioxidants, independent of immune
cell infiltration into islets (24, 31, 32). Cross of the Rpl13a-snoless
alleles into the NOD strain revealed that loss of the snoRNAs was
also protective against the development of hyperglycemia in the
NOD background (Figure 7G). Taken together, our findings provide evidence that the Rpl13a snoRNAs contribute to hyperglycemia in 3 independent murine models of diabetogenesis.

Discussion

Here, we identified noncanonical metabolic roles for box C/D
snoRNAs in the physiological function and pathophysiological
responses of β cells. Although broad loss of box C/D snoRNA–
directed 2′-O-methyl modifications of ribosomal RNAs that results
from fibrillarin knockout is embryonic lethal (2), we demonstrate
that selective loss of 4 snoRNAs in the Rpl13a-snoless model is
compatible with normal murine development. Unexpectedly,
this model revealed a role for Rpl13a-snoRNAs in regulation of
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islet responses to metabolic stress that impacts whole body glucose homeostasis. Furthermore, the snoRNAs also modulate the
response to stimuli that damage islets through oxidative stress,
thereby impacting diabetes susceptibility. Together, these results
establish that box C/D snoRNAs from the Rpl13a locus have noncanonical functions in pancreatic β cells beyond a housekeeping
role in the biosynthesis of ribosomal RNAs. Our findings provide
new insights into islet biology, systemic metabolic homeostasis,
and the pathophysiology of diabetes.
Loss of the Rpl13a-snoRNAs in this model led to enhanced
GSIS in isolated pancreatic islets. Loss of the snoRNAs was also
associated with increased mitochondrial proton leak, lower ROS
tone, and diminished amplification of cellular ROS in response to
high glucose, as well as chemicals that more directly induce ROS.
Uncoupled respiration has been shown to decrease mitochondrial
hydrogen peroxide production during metabolic challenge (17, 18),
providing a precedent for our observations of increased leak and
decreased ROS in the islets. Furthermore, high levels of ROS and
oxidative stress are known to inhibit β cell release of insulin (19–21,
33). Our findings suggest that under stimulatory glucose conditions,
Rpl13a-snoless islets escape this inhibition, because they maintain lower oxidative tone. Together, our results suggest that in the
Rpl13a-snoless model, mitochondrial proton leak leads to lower islet
ROS and greater insulin secretion in the face of metabolic challenge,
with resulting enhanced efficiency of systemic glucose metabolism.
The relationship between ROS and insulin secretion from pancreatic β cells is complex. These specialized cells are characterized
by low-level expression of many antioxidant enzymes yet support
high-level synthesis of a secreted protein that must undergo proper folding and disulfide bond formation in the endoplasmic reticulum, a process that is exquisitely sensitive to changes in cellular
redox state (34–36) Furthermore, ROS function in several different ways to regulate insulin secretion. Findings that stimulatory
glucose levels induce mitochondrial ROS, and antioxidants that
blunt this ROS inhibit GSIS, support a role for ROS as a stimulus
required for GSIS (20, 37). On the other hand, high levels of ROS
that induce oxidative stress impair GSIS, and loss of function of
ROS-producing enzymes or scavenging of ROS potentiates GSIS
(20, 21, 33). Specifically, high levels of ROS have been proposed to
inhibit insulin granule exocytosis and to interfere with stimulussecretion coupling in β cells (38, 39). Our observations of lowered
provoked ROS and improved GSIS in Rpl13a-snoless islets, without
a change in antioxidant potential, suggest that the major impact of
loss of these noncoding RNAs is on production of ROS species that
serve to inhibit insulin secretion.
Rpl13a-snoless mice have germline disruption of Rpl13a sno
RNAs. Thus, although ITT responses were comparable between
the genotypes, effects on systemic glucose homeostasis from tissues other than islets cannot be formally excluded. Given our goal
of precisely removing 4 distinct intronic sequences (ranging from
66 to 89 nucleotides in length) within a genomic space of 2.8 kb,
without disturbing expression of the host protein-coding sequences, we chose to knock in a “snoless” allele. Neither Cre-lox technology nor CRISPR approaches would have been feasible for generation of the 4 simultaneous conditional mutations, as this would
have required generation and interbreeding of 4 distinct knockout
lines to achieve tissue specificity. In our knockin model, howevjci.org   Volume 126   Number 12   December 2016
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Figure 4. Rpl13a-snoless islets demonstrate enhanced glucose-stimulated
insulin secretion. (A) Representative insulin-stained pancreas sections with
morphometric quantification of β cell mass for WT and Rpl13a-snoless (–/–)
mice (n = 4 mice/genotype). Mean + SEM; n = 4 mice/genotype; scale bars:
25 μm. (B) Mean islet protein content (+SEM) quantified in 8 mice/genotype
(10 islets/mouse) obtained from 3 independent experiments. (C) Mean islet
insulin content (+SEM) quantified in 12 mice/genotype (10 islets/mouse)
obtained from 3 independent experiments. (D) Mean islet insulin secretion
(+SEM) in response to low and high glucose quantified in a minimum of 9 mice/
genotype over 3 independent experiments. (E) Mean islet insulin secretion
(+SEM) in response to 30 mM KCl and 1 μM glibenclamide quantified in 3–4
mice/genotype over 3 independent experiments. (F) Changes in Fluo-4–
quantified calcium activity of islets relative to basal, expressed as Δf/f0 for
differing glucose concentrations. Data from 20 independent cells from 4 mice/
genotype. (G) RT-qPCR-quantified expression of Rpl13a snoRNAs and mRNA in
islets (relative to Rplp0). n = 3 independent islet preparations/genotype.
**P < 0.001; *P < 0.05; for –/– vs. WT determined by unpaired t test.
4620
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er, the observations that the snoRNAs are normally expressed in
islets and that their disruption alters GSIS in isolated islets indicate an islet-autonomous role for these noncoding RNAs in GSIS.
These effects at the level of the islet are consistent with the physiological observation of enhanced insulin secretion after glucose
challenge in Rpl13a-snoless mice.
Destruction of pancreatic islets during the development of
type 1 diabetes has been modeled in mice by chemical, genetic,
and immunological perturbations. Although each class of models invokes different pathways leading to β cell destruction and
eventual loss of insulin secretion and hyperglycemia, a common
feature of these pathways is oxidative stress–mediated tissue
damage (24–26, 29, 40). Moreover, improved outcomes following
genetic interventions to decrease β cell ROS provide evidence that
oxidative damage from excessive ROS contributes to destruction
of pancreatic islets. Observations in humans of elevated plasma
and red blood cell markers of ROS during the first weeks following the onset of symptoms of type 1 diabetes also implicate oxidative stress in the pathogenesis of diabetes (27). Our findings in
Rpl13a-snoless mice of lower oxidative stress, less β cell death, and
improved glucose tolerance following chemical provocation of
diabetes and decreased hyperglycemia in genetic models of diabetogenesis raise the possibility that these noncoding RNAs function
in the progressive β cell damage that leads to diabetes.
Based on the well-characterized biology of canonical sno
RNAs, the Rpl13a snoRNAs likely form ribonucleoprotein particles that target cellular RNAs for modifications. Although our
study links the snoRNAs to altered mitochondrial function and
ROS production, the precise molecular targets of these snoRNAs
responsible for the observed physiological phenotypes remain
to be determined. Beyond the predicted 28S and 18S ribosomal
RNA targets for these snoRNAs (41), the Rpl13a snoRNAs may
also function non-canonically to target mRNAs, given recent
studies demonstrating that some snoRNAs target mRNAs (42,
43) and our previous observation that the Rpl13a snoRNAs accumulate in the cytoplasm under metabolic stress conditions (12).
Our RNAseq analysis suggests that rather than affecting the
abundance of potential mRNA targets, the Rpl13a snoRNAs may
impact their translation potential. Ongoing efforts are focused
on high-throughput biochemical analyses of snoRNAs engaged
with their relevant targets in WT tissues, studies for which the
Rpl13a-snoless model will serve as a rigorous control. However, these approaches will be addressed in future studies, as
they require substantially greater material than can be obtained
from isolated islets (44). Furthermore, the Rpl13a snoRNAs may
also contribute to metabolic stress–induced alterations in β cell
growth and survival by binding to and activating protein kinase
RNA-activated (PKR) to affect downstream protein translation
and signaling pathways (45–48).
This study provides insights into the disease relevance and
underlying cellular functions of snoRNAs in vivo. Our findings
challenge the paradigm that box C/D snoRNAs serve solely to
catalyze nucleotide modifications and processing of structural
RNAs. The striking effects of loss of function of the Rpl13a sno
RNAs raise the possibility that genetic variation affecting the production or function of these and other snoRNAs may contribute
to metabolic disease phenotypes in mammals. Furthermore, giv-
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Figure 5. Increased mitochondrial leak
in Rpl13a-snoless islets. (A) OCR of WT
and –/– islets at 3 mM glucose with
injection of oligomycin (OM), FCCP, and
rotenone and antimycin A (Rot/AntA).
Data points in line graphs (left) represent
mean values (±SEM) from 3 independent
experiments in which islets pooled by
genotype were used to generate a total
of 9 (WT) or 8 (–/–) technical replicates
from n = 11 WT and n = 12 –/– mice.
Bar graphs (right) report calculated
mean (+SEM) oxygen consumption for
basal and maximal (Max) respiration,
proton leak, ATP production and spare
respiratory capacity. (B) OCR of WT and
–/– islets at 20 mM glucose, as in A. Data
points from 3 independent experiments
in which islets pooled by genotype were
used to generate a total of 9 (WT) or
11 (–/–) technical replicates from n = 13
WT and n = 14 –/– animals. Graphs as in
A. (C) OCR of WT and –/– islets initially
maintained at 3 mM glucose; this was
changed at the time indicated to 20 mM
glucose. Data points represent mean
values (±SEM) from 3 independent
experiments in which islets pooled by
genotype generated 12 (WT) or 8 (–/–)
technical replicates from n = 15 WT and
n = 10 –/– animals. *P < 0.05 for –/– vs.
WT; **P < 0.01 for –/– vs. WT determined
by unpaired t test.

en that snoRNAs can be targeted for antisense knockdown, our
findings suggest that molecular therapies could be designed to
target these noncoding RNAs.

Methods

Mice. To generate mice lacking all 4 Rpl13a snoRNAs, we created a targeting vector containing the Rpl13a sequence between exons 1 and 8
with a loxP-flanked neomycin phosphotransferase (NEO) cassette in
intron 1, and lacking the U32a, U33, U34, and U35a snoRNAs in introns
2, 4, 5, and 6, respectively. The construct was electroporated into
129S5/SvEv ES cells. ES cells with the correct homologous recombination event were selected by neomycin resistance, PCR, and Southern
blot analysis. ES clones with normal karyotype were microinjected into
B6/FBN blastocysts that were implanted into pseudopregnant females.
F1 progeny from the resulting chimeras were tested for the presence of
the NEO cassette in the Rpl13a locus by Southern blot analysis. The
NEO cassette was removed by breeding these mice with mice expressing CRE under the adenovirus EIIa promoter. Heterozygote progeny
were backcrossed into the FVB/N strain more than 10 generations. See
Supplemental Table 3 for genotyping primers. Mice generated from
heterozygote-heterozygote breeding pairs were used for experiments.
The Rpl13a-snoless mice were crossed with Akita mice bearing the
Ins2C96Y allele, which had previously been backcrossed onto the FVB
background for more than 9 generations (FVB.B6-Ins2Akita/MlnJ;
The Jackson Laboratory). NOD (NOD/ShiLtJ) mice from the Jackson
Laboratory were bred in the Immunology of Type 1 Diabetes Core of

the Washington University Diabetes Research Center. Speed Congenics (49) was used to move the Rpl13a-snoless allele onto the NOD
background strain, using a marker-assisted breeding strategy. At each
generation, multiple offspring were analyzed for genomic single nucleotide polymorphisms to select subsequent breeders with the highest
percentage of NOD. After 6 generations, animals were >98.2% NOD.
NOD/Rpl13a+/– breeders were used to generate female progeny for
studies. Diabetic mice were identified based on two consecutive random blood glucose measures of ≥250 mg/dl.
RT-qPCR. Total RNA was isolated using TRIzol reagent. For
mRNA analyses, cDNA synthesis used the SuperScript First-Strand
Synthesis System with oligo(dT) priming (Invitrogen). For snoRNA
analyses, stem-loop primers were used for reverse transcription, as
previously described (10, 50). Quantitative RT-PCR (RT-qPCR) was
performed using SYBR Green PCR Master Mix (Applied Biosystems)
and an ABI Prism 7500 Fast Real-Time PCR System. Relative quantification of gene expression was performed using the comparative
threshold method. See Supplemental Table 3 for RT-qPCR primers.
Immunoblot analyses. Tissues were homogenized in RIPA buffer (150 mM NaCl, 50 mM HEPES pH 7.4, 1% Nonidet P-40, 0.1%
SDS, 0.5% sodium deoxycholate, 1× Protease Complete [Roche],
1 mM phenylmethylsulfonyl fluoride). Proteins were separated by
SDS-PAGE, transferred to nitrocellulose using the semi-dry method,
blocked with dry milk, and immunoblotted with polyclonal rabbit
α–hamster RPL13a antibody (1:2,000) (10) and monoclonal α-actin
(Sigma-Aldrich). Detection used HRP-conjugated secondary antijci.org   Volume 126   Number 12   December 2016
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Figure 6. Rpl13a-snoless islets are ROS resistant. (A) Representative images of WT and –/– islets (n = 3 mice/genotype) stained for superoxide with DHE. Scale
bar: 50 μm. Graph shows mean fluorescence (+SEM) of WT and –/– islets for n = 6 random fields/genotype in each of 2 independent experiments. (B and C) DCF
and DHE staining of dispersed islets at baseline and following treatment for 2 hours with 100 μM H2O2 (B) or 25 μM menadione (mdn; C). Mean (+SEM) of data
from a minimum of 3 independent experiments. (D) DCF staining (mean + SEM) of dispersed islets incubated for 2 hours with 3 mM or 20 mM glucose. Data from
3 independent experiments. *P < 0.05 for –/– vs. WT; #P < 0.05 for treated vs. untreated (within a genotype) determined by unpaired t test.

bodies (Jackson ImmunoResearch Laboratories) and Western Lightning Plus-ECL (PerkinElmer Life Sciences) reagent. Images were
digitally captured using a Bio-Rad ChemiDoc MP and analyzed with
Bio-Rad Image Lab software.
Islet isolation. Pancreases were inflated with ice-cold collagenase
(Sigma-Aldrich) buffer (0.45 mg/ml collagenase in HBSS without
Ca2+) and digested at 37°C. Islets were collected after sequential washes and incubated overnight in RPMI media (with 10% FBS and 2 mM
l-glutamine) until use (51). Islets of equal size were hand picked to
generate 3–5 technical replicates (measures, wells) for all experiments.
Very large and very small islets were excluded. Results are reported for
a minimum of 3 independent experiments.
Insulin secretion assay. Hand-picked islets were distributed into
0.4-μm Transwells of a 24-well plate containing Krebs-Ringer buffer (KRB) without glucose. After washing twice in 2.8 mM glucose,
islets were sequentially incubated in 5.6 mM and 16.7 mM glucose
for 1 hour each (52). For KCl and glibenclamide experiments, islets
were incubated first in 5.6 mM glucose and then 30 mM KCl or 1 μM
glibenclamide (Sigma-Aldrich). A Rat/Mouse Insulin ELISA kit (Millipore) was used to measure the insulin levels in media.
Calcium imaging of islets. Hand-picked islets were loaded with 4
μM Fluo-4 (Invitrogen) in KRB with 20 mM HEPES and 0.1% BSA,
pH 7.4, for 40 minutes and then imaged on a Zeiss LSM 880 confocal microscope (Plan-Apochromat 20× M27, NA0.8 objective) in 2,
5, 8, and 16 mM glucose, with analyses as previously described (53).
Following a 6-minute incubation at each concentration, a 5-minute
time series was acquired, and 20 mM KCl was injected at the end of
acquisition to prime maximum calcium release. Data were analyzed
using ImageJ (NIH) and averaged over 20 cells in 6 different islets
from each of 4 different mice per genotype. Data are expressed as
fluorescence intensity under each condition relative to basal (nontreated) conditions.
ROS detection from whole islets or dispersed islet cells. For whole islets,
equivalent numbers of hand-picked islets of each genotype were incubated in media containing 10 μM DHE (Molecular Probes) for 1 hour,
washed with PBS, and mounted. Epifluorescence images were obtained
using a Zeiss Axioskop, and DHE fluorescence was quantified in 6 random fields per sample using ImageJ. For dispersed islets, equivalent
numbers of cells of each genotype (pooled from multiple animals)
were plated in RPMI media in 96-well plates overnight, incubated with
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10 μM DHE or 10 μM H2DCFDA (DCF; Molecular Probes) for 1 hour,
and then treated with 100 μM H2O2 (Sigma-Aldrich) for 2 hours. Fluorescence was quantified in each well using a TECAN plate reader. To
detect ROS production in low- (3 mM) or high-glucose (20 mM) conditions, dispersed islets were plated on poly-d-lysine–coated (SigmaAldrich) glass-bottom culture dishes (MatTek Corp.). After overnight
culture, islets were incubated in KRB containing 3 mM or 20 mM glucose with 10 μM DCF for 1 hour at 37°C. Immediately after washing,
fluorescence images were obtained using a Leica DMIRB microscope.
DCF fluorescence of individual islet cells from 8–10 random fields per
condition was quantified using Leica Application Suite AF (19).
Trolox equivalent antioxidant capacity. Antioxidant capacity was
quantified in lysates from hand-picked islets (n = 4 mice/genotype)
as described previously, and values are reported per microgram
islet protein (54).
RNAseq analysis of islets. High-quality total RNA (RNA integrity number [RIN] ≥8.5) was prepared from hand-picked islets (n = 4
mice/genotype) using TRIzol reagent, treated with TURBO DNAse
(Thermo Fisher), and used to prepare SeqPlex RNAseq libraries
(Sigma-Aldrich). Sequencing was performed by the Washington
University Genome Technology Access Center using two lanes of
Illumina HiSeq 2500. Reads were demultiplexed and trimmed, and
STAR alignment and quantification analysis were carried out using
the Partek Flow platform. Uniquely aligned reads were quantified to
identify genes with at least a 2-fold change between genotypes, with
P < 0.05 and an FDR step-up of 0.05. Genes identified were further
analyzed for potential U32a, U33, U34, and U35a snoRNA target sites
using the PLEXY program and a cut-off of minimum free energy for
predicted duplexes of less than –20.4 kcal/mol (22). Sequence data are
available in the NCBI’s Gene Expression Omnibus (GEO GSE87354).
Streptozotocin treatment. Eight-week-old female mice were injected with streptozotocin intraperitoneally (Sigma-Aldrich; 50 mg/kg in
0.1 M Na citrate, pH 4.5) for 5 consecutive days as previously described
(55). Control animals received buffer only. Serial fasting blood glucose
and body weight were quantified every 2 weeks; GTT was performed
at 8 weeks after the streptozotocin injection, and pancreases were harvested for histological analysis.
Intraperitoneal GTT and ITT. In vivo dynamic testing was carried out following a 4-hour fast using standard procedures of the
NIH-sponsored National Mouse Metabolic Phenotyping Centers

Downloaded from http://www.jci.org on January 4, 2017. https://doi.org/10.1172/JCI88069

The Journal of Clinical Investigation  

RESEARCH ARTICLE

Figure 7. Rpl13a-snoless mice are resistant to diabetogenic stimuli. (A–E) streptozotocin- (STZ-) or vehicle-treated (control) 8-week-old WT and –/– mice. (A)
Mean fasting blood glucose over time (+SEM) for n = 9 mice per genotype/treatment. (B) Mean blood glucose (+SEM) during GTT at 16 weeks for n = 9 mice per genotype/treatment. (C) Representative pancreas sections stained for 4-hydroxynonenal 5 days after STZ. Scale bar: 25 μm (n = 4 mice per genotype/treatment). (D)
Pancreas tissue triol 5 days after STZ for n = 7 mice per genotype/treatment. (E) Representative pancreas sections stained for TUNEL 5 days after STZ. Scale bar:
25 μm. Quantification for n = 4 mice per genotype/treatment. Magnification ×2. (F) Ins2C96Y Akita allele bred into Rpl13a-snoless model. Mean (+SEM) random blood
glucose at indicated time points for a minimum of n = 7 per group. (G) Rpl13a-snoless alleles were bred into the NOD model. Diabetes-free survival over 24 weeks
for NOD (n = 26) vs. NOD Rpl13a-snoless (n = 16) female mice. *P < 0.05 for (–/–, STZ) vs. (WT, STZ); **P < 0.05 for (WT, STZ) vs. (WT); #P < 0.001 for (WT, C96Y) vs.
(WT); †P < 0.0005 for (–/–, C96Y) vs. (WT, C96Y); determined by unpaired t test. §P < 0.04 by log-rank testing.

(http://www.mmpc.org/shared/protocols.aspx). Mice were injected intraperitoneally with 1 g/kg glucose (GTT) or 1 U/kg insulin
(ITT). Blood glucose was measured at 0, 15, 30, 60, and 120 minutes after the injection using a glucometer (Contour). Serum was
analyzed for insulin at 0 and 30 minutes of GTT at the Washington University Diabetes Research Center Immunoassay Core by a
sensitive Singulex single molecule tracking method that has a lower
limit of quantification of 19 pg/ml.
Histological and immunofluorescence analyses. For histological
analyses, 5-μm sections of formalin-fixed, paraffin-embedded pancreas tissues were stained with H&E. For TUNEL, sections were
labeled with TUNEL reagent (Cell Death Detection Kit TMR, Roche),
followed by overnight incubation with α-insulin antibodies (polyclonal guinea pig antibody, 1:200, Dako IR002). TUNEL-positive
signals were quantified from >75 islets per condition (n = 4 mice
[>5,000 nuclei]/genotype/condition). Proliferation was analyzed

with α–Ki-67 antibodies (anti-rabbit monoclonal IgG, 1:200, Cell
Signaling Technology 9129), quantified from >75 islets per condition
(n = 4 mice [>3,500 nuclei]/genotype/condition). Secondary antibodies were Alexa Flour 488–goat anti-guinea pig and Alexa Fluor 594–
goat anti-rabbit (Molecular Probes A-11073 and A-11037). Stained sections were examined using an Olympus FSX100 microscope.
Morphometry. Morphometric analysis of pancreases from 8-week-old
mice was performed as previously reported (56). For measurement of β
cell mass, every 40th pancreatic section was immunostained with guinea pig anti-insulin antibody (1:100, Invitrogen) and counterstained with
hematoxylin. The β cell mass for each mouse was quantified using Image
Pro Plus software (Media Cybernetics) by obtaining the fraction of the
cross-sectional area of pancreatic tissue (exocrine and endocrine) positive
for insulin staining and then multiplying by the pancreatic weight.
Isolation of MEFs and ROS detection. MEFs were harvested
from embryos at E13.5 and cultured in DMEM with 10% FBS, 2 mM
jci.org   Volume 126   Number 12   December 2016
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l-glutamine, 1× MEM non-essential amino acids, and 150 μM
monothioglycerol. ROS was quantified in low-passage (≤5) MEFs by
staining with 10 μM DCF or 5 μM MitoSOX Red (Life Technologies)
for 5 minutes in PBS with Ca2+/Mg2+. Fluorescence intensity was quantified by flow cytometry (BD FACSCalibur), measuring mean signal
intensity for 104 events in each sample, and normalized to WT cells.
Oxidative tissue damage. Formalin-fixed pancreatic sections were
costained for insulin (polyclonal guinea pig antibody, 1:200, Dako) and
hydroxynonenal (rabbit polyclonal, 1:100, Abcam) using appropriate
Alexa Fluor–coupled secondary antibodies (Molecular Probes). Triol was
quantified per mg pancreas tissue and is reported per mg protein (57).
Mitochondrial DNA copy number. Relative mitochondrial DNA
content was measured from isolated islets using RT-qPCR and nuclear
DNA content as an internal control, as described previously (58).
OCR. Oxygen consumption of islets was measured using a
Seahorse XF24 analyzer (Seahorse Bioscience) (15). Fifty islets were
hand picked and washed once in assay media containing 1% FBS and
1 mM l-glutamine, and 3 mM or 20 mM glucose, and then transferred
into the depressed well of an XF24 Islet Capture Microplate. OCR was
measured at basal glucose levels, as well as with drugs acting on the
respiratory chain: oligomycin (ATP synthase inhibitor; 5 μM), FCCP
(uncoupler; 7.5 μM), rotenone (complex I inhibitor; 0.1 μM), and antimycin A (complex III inhibitor; 1 μM) — all from Sigma-Aldrich. After
the assay, islets were washed once with PBS, and protein was quantified by microBCA assay (Pierce).
Electron microscopy. Islets were fixed in a modified Karnovsky’s
fixative of 3% glutaraldehyde, 1% paraformaldehyde in 0.1 M sodium
cacodylate buffer; post-fixed in 2% osmium tetroxide in 0.1 M sodium
cacodylate buffer; stained with 2% aqueous uranyl acetate for 30 minutes; dehydrated in graded acetone; and embedded in Poly/Bed 812
(Polysciences Inc.). 90-nm sections were examined by a JEOL model
1200EX electron microscope. Digital images were acquired using the
AMT Advantage HR (Advanced Microscopy Technology) high-definition
CCD, 1.3 megapixel TEM camera.
Statistics. Results are presented as mean ± SEM for a minimum of
3 independent experiments. Statistical significance was assessed by
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